Overall market sentiment has been down on Protara Therapeutics Inc (TARA) stock lately. TARA receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Protara Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on TARA!
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With TARA Stock Today?
Protara Therapeutics Inc (TARA) stock is down -1.67% while the S&P 500 is up 0.05% as of 10:33 AM on Friday, Aug 11. TARA is down -$0.04 from the previous closing price of $2.39 on volume of 12,458 shares. Over the past year the S&P 500 is up 6.20% while TARA is down -31.69%. TARA lost -$5.94 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Protara Therapeutics Inc click here.
More About Protara Therapeutics Inc
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Click Here to get the full Stock Report for Protara Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
